Linden Lake Labs

Linden Lake Labs operates as a biotech venture studio and life sciences platform, building high-impact companies from early scientific discoveries to commercialization. The firm translates breakthrough science into scalable, capital-efficient businesses, accelerating novel therapies and technologies to patients worldwide. Its hands-on approach de-risks and advances promising ventures across critical therapeutic areas like oncology, CNS disorders, and rare diseases.

Co-founded in 2024 by Thomas Haag and Abhishake Chhibber, Linden Lake Labs was established to bridge the gap between early scientific innovation and commercial viability. Thomas Haag, a biotechnology executive and investor, along with Abhishake Chhibber, a seasoned biotech strategic advisor, created this platform. Their core insight aimed to systematically develop nascent life science ventures into impactful entities.

The platform ultimately serves patients globally by bringing novel therapies and technologies to market through its portfolio companies. Linden Lake Labs envisions building a diversified pipeline of scalable life science businesses, ensuring scientific breakthroughs rapidly translate into tangible patient benefits. The firm’s long-term objective is to drive significant advancements in human health using its focused venture studio model.